State of Alaska Department of Revenue’s Viking Therapeutics VKTX Stock Holding History

State of Alaska Department of Revenue’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$150K	Buy	+3,848	New	+$124K	﹤0.01%	1693

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State of Alaska Department of Revenue's VKTX Position: Q2 2026 in Review

State of Alaska Department of Revenue opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 3,848 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #1693 among its holdings.

281 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

State of Alaska Department of Revenue held 3,848 shares of Viking Therapeutics worth $150K as of Q2 2026.
Viking Therapeutics was a new State of Alaska Department of Revenue position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1693 holding.
281 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.